惡性腫瘤為國人死因之首，其有效的治療方式為一迫切待解決的課題。本論文藉由四環黴素類藥物（Tetracycline）抑制癌細胞分泌基質金屬蛋白酶以達到抑制腫瘤生長的效果。由明膠蛋白酵素電泳法發現去氧羥四環素（Doxycycline）為四種四環黴素中抑制癌細胞分泌基質金屬蛋白酶效率最高之藥物，其具有顯著抑制人類口腔癌細胞SCC-15分泌MMP-9及MMP-2的功效；但對小鼠膀胱癌細胞MBT-2的效果卻不顯著。去氧羥四環素在本論文細胞增生檢測的濃度範圍內（2.5~160 μg/ml）具有抑制SCC-15及MBT-2增生的效果，但卻不影響正常人類纖維母細胞細胞MRC-5的增生。異種移植的小鼠實驗亦證實以皮下注射方式高劑量（每日3 mg）地投與去氧羥四環素於腫瘤附近，可以顯著地抑制SCC-15腫瘤生長；但對MBT-2腫瘤抑制效果則不顯著，此與體外的結果相符。這說明基質金屬蛋白酶在腫瘤生長步驟中扮演一重要角色，其表現及活性顯著影響腫瘤生長。

Cancer is the leading cause of death in Taiwan. It’s a serious problem that we should solve as soon as possible. In this article we used Tetracyline as matrix metalloproteinase(MMP) inhibitors to inhibit the growth of tumor. Among four Tetracyclines, Doxycycline is the most potent inhibitor for inhibiting cancer cell secretion of MMP which was detected by Zymography. Doxycycline significantly inhibits the secretion of MMP-9 and MMP-2 from the human oral squamous cell carcinoma, SCC-15, but it didn’t show the same effect on murine bladder cancer cell line, MBT-2. In the cell proliferation assay, Doxycycline inhibits proliferation of SCC-15 and MBT-2, but it can not inhibit proliferation of normal human lung fibroblast, MRC-5, in the various concentration(2.5~160 μg/ml) tested. We also demonstrate that daily subcutaneous administration of Doxycycline(3 mg/mice) significantly restrained the growth of SCC-15 xenograft tumor, but not MBT-2 xenograft tumor. These in vivo results are consistent with the in vitro data. These indicate that MMP plays an important role in tumor growth. The expression and activity of MMP significantly influence the growth of tumor.

1.Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010,141:52-67.
2.Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA A Cancer Journal for Clinicians 2004,54:8-29.
3.行政院衛生署. 歷年死亡原因. 2010.
4.行政院衛生署. 民國98年死因結果分析. 2010.
5.Chiang AC, Massague J. Molecular basis of metastasis. The New England Journal of Medicine 2008,359:2814-2823.
6.Gerald K. The Interaction Between Cells and Their Environment. In: Cell and Molecular Biology: Concepts and Experiments: John Wiley & Sons; 2007. pp. 242.
7.Lia NG, Shib ZH, Tang YP, Duan JA. Selective matrix metalloproteinase inhibitors for cancer. Current Medicinal Chemistry 2009,16:3805-3827.
8.Ethell IM, Ethell DW. Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. Journal of Neuroscience Research 2007,85:2813-2823.
9.Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Molecular and Cellular Biochemistry 2003,253:269-285.
10.Snoek-van Beurden PAM, Von den Hoff JW. Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques 2005,38:73-83.
11.Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. The Federation of European Biochemical Societies Journal 2011,278:16-27.
12.Griffin MO, Fricovsky E, Ceballos G, Villarreal F. Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. American Journal of Physiology - Cell Physiology 2010,299:C539-548.
13.Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochimica et Biophysica Acta 2000,1477:267-283.
14.Jonat C, Chung FZ, Baragi VM. Transcriptional downregulation of stromelysin by tetracycline. Journal of cellular biochemistry 1996,60:341-347.
15.Hanemaaijer R, Sorsa T, Konttinen YT, Ding YL, Sutinen M, Visser H, et al. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells - Regulation by tumor necrosis factor-alpha and doxycycline. Journal of Biological Chemistry 1997,272:31504-31509.
16.Shen LC, Chen YK, Lin LM, Shaw SY. Anti-invasion and anti-tumor growth effect of doxycycline treatment for human oral squamous-cell carcinoma--in vitro and in vivo studies. Oral oncology 2010,46:178-184.
17.Fife RS, Sledge GW, Jr., Roth BJ, Proctor C. Effects of doxycycline on human prostate cancer cells in vitro. Cancer Letters 1998,127:37-41.
18.Fife RS, Sledge GW, Jr. Effects of doxycycline on cancer cells in vitro and in vivo. Advances in Dental Research 1998,12:94-96.
19.Lokeshwar BL, Selzer MG, Zhu BQ, Block NL, Golub LM. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. International Journal of Cancer 2002,98:297-309.
20.Rubins JB, Charboneau D, Alter MD, Bitterman PB, Kratzke RA. Inhibition of mesothelioma cell growth in vitro by doxycycline. The Journal of Laboratory and Clinical Medicine 2001,138:101-106.
21.Seftor RE, Seftor EA, De Larco JE, Kleiner DE, Leferson J, Stetler-Stevenson WG, et al. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clinical & Experimental Metastasis 1998,16:217-225.
22.Duivenvoorden WC, Popovic SV, Lhotak S, Seidlitz E, Hirte HW, Tozer RG, et al. Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer. Cancer Research 2002,62:1588-1591.
23.Wang-Gillam A, Siegel E, Mayes DA, Hutchins LF, Zhou YH. Anti-Tumor Effect of Doxycycline on Glioblastoma Cells. Journal of Cancer Molecules 2007,3:147-153.
24.Smilack JD. The tetracyclines. Mayo Clinic Proceedings 1999,74:727-729.
25.Duggar BM. Aureomycin; a product of the continuing search for new antibiotics. Annals of the New York Academy of Sciences 1948,51:177-181.
26.Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. Journal of the American Academy of Dermatology 2006,54:258-265.
27.Vidal A, Sabatini M, Rolland-Valognes G, Renard P, Madelmont JC, Mounetou E. Synthesis and in vitro evaluation of targeted tetracycline derivatives: effects on inhibition of matrix metalloproteinases. Bioorganic & Medicinal Chemistry 2007,15:2368-2374.
28.Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R, et al. Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. Journal of Periodontal Research 1983,18:516-526.
29.Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Critical Reviews in Oral Biology and Medicine : an Official Publication of the American Association of Oral Biologists 1991,2:297-321.
30.Ramamurthy NS, Zebrowski EJ, Golub LM. The effect of alloxan diabetes on gingival collagen metabolism in rats. Archives of Oral Biology 1972,17:1551-1560.
31.McNamara TF, Ramamurthy NS, Mulvihill JE, Golub LM. The development of an altered gingival crevicular microflora in the alloxan-diabetic rat. Archives of Oral Biology 1982,27:217-223.
32.Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proceedings of the National Academy of Sciences of the United States of America 1999,96:13496-13500.
33.Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proceedings of the National Academy of Sciences of the United States of America 1998,95:15769-15774.
34.Tamargo RJ, Bok RA, Brem H. Angiogenesis inhibition by minocycline. Cancer Research 1991,51:672-675.
35.Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, Trauger JW. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. Journal of Neurochemistry 2005,94:819-827.
36.Kroon AM, Dontje BHJ, Holtrop M, Vandenbogert C. The Antitumour Action of Doxycycline. Drugs under Experimental and Clinical Research 1984,10:759-766.
37.Leber TM, Balkwill FR. Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels. Analytical Biochemistry 1997,249:24-28.
38.Descamps FJ, Martens E, Opdenakker G. Analysis of gelatinases in complex biological fluids and tissue extracts. Laboratory Investigation 2002,82:1607-1608.
39.Goldberg GI, Strongin A, Collier IE, Genrich LT, Marmer BL. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. Journal of Biological Chemistry 1992,267:4583-4591.
40.Jacob D, Davis J, Fang B. Xenograftic tumor models in mice for cancer research, a technical review. Gene Therapy and Molecular Biology 2004,8:213-219.
41.Thomas GT, Lewis MP, Speight PM. Matrix metalloproteinases and oral cancer. Oral oncology 1999,35:227-233.
42.Hong SD, Hong SP, Lee JI, Lim CY. Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential. Oral oncology 2000,36:207-213.
43.Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, Gallo O. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer 2002,95:1902-1910.
44.Katayama A, Bandoh N, Kishibe K, Takahara M, Ogino T, Nonaka S, et al. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clinical Cancer Research 2004,10:634-640.
45.Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clinical Cancer Research 2004,10:3110-3116.
46.Kato K, Hara A, Kuno T, Kitaori N, Huilan Z, Mori H, et al. Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: manifestation and localization of their activity. Journal of Cancer Research and Clinical Oncology 2005,131:340-346.
47.Overall CM, Sodek J. Concanavalin A produces a matrix-degradative phenotype in human fibroblasts. Induction and endogenous activation of collagenase, 72-kDa gelatinase, and Pump-1 is accompanied by the suppression of the tissue inhibitor of matrix metalloproteinases. Journal of Biological Chemistry 1990,265:21141-21151.
48.Grant MB, Caballero S, Tarnuzzer RW, Bass KE, Ljubimov AV, Spoerri PE, et al. Matrix metalloproteinase expression in human retinal microvascular cells. Diabetes 1998,47:1311-1317.
49.Burns FR, Stack MS, Gray RD, Paterson CA. Inhibition of purified collagenase from alkali-burned rabbit corneas. Investigative Ophthalmology & Visual Science 1989,30:1569-1575.
50.Brion M, Lambs L, Berthon G. Metal ion-tetracycline interactions in biological fluids. Part 5. Formation of zinc complexes with tetracycline and some of its derivatives and assessment of their biological significance. Agents and Actions 1985,17:229-242.
51.Nagase H, Enghild JJ, Suzuki K, Salvesen G. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. Biochemistry 1990,29:5783-5789.
52.English JL, Kassiri Z, Koskivirta I, Atkinson SJ, Di Grappa M, Soloway PD, et al. Individual Timp deficiencies differentially impact pro-MMP-2 activation. Journal of Biological Chemistry 2006,281:10337-10346.
53.Shan B, Hagood JS, Zhuo Y, Nguyen HT, MacEwen M, Morris GF, et al. Thy-1 attenuates TNF-alpha-activated gene expression in mouse embryonic fibroblasts via Src family kinase. Public Library of Science One 2010,5:e11662.
54.Stuelten CH, DaCosta Byfield S, Arany PR, Karpova TS, Stetler-Stevenson WG, Roberts AB. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. Journal of Cell Science 2005,118:2143-2153.
55.Cruz-Munoz W, Sanchez OH, Di Grappa M, English JL, Hill RP, Khokha R. Enhanced metastatic dissemination to multiple organs by melanoma and lymphoma cells in timp-3-/- mice. Oncogene 2006,25:6489-6496.
56.Liao J, Wolfman JC, Wolfman A. K-ras regulates the steady-state expression of matrix metalloproteinase 2 in fibroblasts. Journal of Biological Chemistry 2003,278:31871-31878.
57.Almazin SM, Dziak R, Andreana S, Ciancio SG. The effect of doxycycline hyclate, chlorhexidine gluconate, and minocycline hydrochloride on osteoblastic proliferation and differentiation in vitro. Journal of Periodontology 2009,80:999-1005.
58.Babich H, Tipton DA. In vitro response of human gingival epithelioid S-G cells to minocycline. Toxicology in Vitro : an International Journal Published in Association with BIBRA 2002,16:11-21.
59.Chang WY, Clements D, Johnson SR. Effect of doxycycline on proliferation, MMP production, and adhesion in LAM-related cells. American Journal of Physiology. Lung Cellular and Molecular Physiology. 2010,299:L393-400.
60.Lee N, Woodrum CL, Nobil AM, Rauktys AE, Messina MP, Dabora SL. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BioMed Central Pharmacology 2009,9:8.